Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-19-129523
Filing Date
2019-04-30
Accepted
2019-04-30 16:39:02
Documents
7
Effectiveness Date
2019-04-30

Document Format Files

Seq Description Document Type Size
1 DEFA14A d726921ddefa14a.htm DEFA14A 43553
2 GRAPHIC g726921page3a.jpg GRAPHIC 2784
3 GRAPHIC g726921page3b.jpg GRAPHIC 1292
4 GRAPHIC g726921page4a.jpg GRAPHIC 2817
5 GRAPHIC g726921page4b.jpg GRAPHIC 1443
6 GRAPHIC g726921page5.jpg GRAPHIC 1435
7 GRAPHIC g726921page6.jpg GRAPHIC 1427
  Complete submission text file 0001193125-19-129523.txt   61061
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-24006 | Film No.: 19782420
SIC: 2834 Pharmaceutical Preparations